Gain Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GANX Nasdaq 2830 www.gaintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update - Nov 14th, 2024 9:05 pm
Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2 - Oct 23rd, 2024 12:00 pm
Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics - Oct 15th, 2024 11:00 am
Gain Therapeutics to Present at Michael J. Fox Foundation’s 16th Annual Parkinson’s Disease Therapeutics Conference - Oct 9th, 2024 12:30 pm
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - Oct 7th, 2024 11:00 am
Gain Therapeutics to Participate at Upcoming Investor Conferences - Oct 3rd, 2024 11:00 am
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers - Sep 30th, 2024 11:00 am
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease - Sep 26th, 2024 11:00 am
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024 - Sep 19th, 2024 11:00 am
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 11:00 am
Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial - Aug 30th, 2024 8:52 am
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease - Aug 29th, 2024 11:30 am
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update - Aug 8th, 2024 11:30 am
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference - Aug 1st, 2024 12:00 pm
7 Sorry Biotech Stocks Set to Make Investors Sad - Jul 22nd, 2024 11:00 am
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease - Jul 9th, 2024 11:00 am
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Jul 8th, 2024 4:00 pm
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 - Jun 28th, 2024 8:39 pm
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO - Jun 27th, 2024 8:08 pm
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease - Jun 27th, 2024 12:35 pm